BRAF and colorectal carcinoma: The most frequent actionable lesions were activating BRAF mutations (V600E, n = 14; D594G, n = 2; 30.2%, 14/16 occurred in patients with CRC), activating FGFR2 mutations (n = 2) or FGFR2 fusions (n = 8) (18.8%, all of which occurred in patients with CCA), and microsatellite instability/dMMR (17%), as assessed by PCR and immunohistochemistry (Fig. 3b, c).